molecules potentially important novel targets for therapeutic intervention in cancer." Eugenio Sangiorgi and Genomics and Genetics Faculty Member, Giovanni Neri, explains that the authors. "...used a wide range of techniques from iPS to a transgenic mouse model for Down's syndrome to a KO mouse for Dscrl,